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or poor-tolerated AFL Clinical history, other arrhythmias as atrial fibrillation
(AF), data of echocardiography were collected. The patients were followed
from 3 months up to 10 years.
Results: Women tended to be older than men (65.5±12 vs 64±11.5 years)
(p< 0.08). Underlying HD was as frequent in women as in men (76%). HD
nature differed: women had more congenital HD (10 vs 2%, p<0.0001), more
valvular HD (17.5 vs 10% p<0.002) and less respiratory failure (4.5 vs 10%)
(p<0.01), less ischemic HD (5 vs 20%)(p<0.0000) than men. Hypertensive HD,
dilated cardiomyopathy or various HD’s did not differ. Previous history of AF
was more frequent in women (31.5%) than in men (26%) (p<0.012). AFl-
related rhythmic cardiomyopathy tended to be less frequent in women than in
men (4 vs 8%) (p<0.07). Presentation with 1/1 AFl was as frequent in women
as in men (10% vs 7%). AFl ablation-related major complications as complete
AV block, death or cardiac shock were more frequent in women than in men
(4 vs 1%)(p<0.004). After 3±3 years, AFl recurrences tended to be less fre-
quent in women than in men (8.5 vs 13%)(p<0.06). AF occurrence was more
frequent in women than in men (24 vs 14%)(p<0.0002). Among these patients
66% of women and men had no history of AF before AFl ablation. Their risk
of AF remains higher in women than in men (16% vs 8%)(p<0.007).
Conclusions: There gender-related differences in the prevalence, clinical
presentation, ablation-related complications and AF incidence. AFL is less
common in women than in men, despite similar age and as frequent under-
lying HD. The risk of AFl ablation-related major complications is higher in
women than in men. Women have more frequently history of AF and an inde-
pendent higher risk than men of developing AF after ablation of atrial flutter.
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Introduction: Studies have documented the underuse of oral anticoagulant
therapy (OAC) as stroke prophylaxis in older persons with history of atrial
fibrillation (AF). Failure to prescribe OAC is often due to the perception by
physicians of bleeding because of specific older people clinical factors.
We performed a prospective observational study in the University Hospital
of Reims, whose aim was to evaluate the management of thromboembolic risk
in older patients in everyday-life hospital practice and impact of frailty and
dependence objective parameters.
Method: 150 AF patients over 75 years were consecutively included over
a period of four months. Clinical and biological data, risk scores for bleeding
(HASBLED) and thrombo-embolic events (CHADS and CHADSVASc) were
computed. Several scores and parameters of assessment of autonomy and risk
of falling were independently recorded: MMS (Mini-Mental Status), ADL
(Activities of Daily Living) and IADL (Instrumental ADL).
Results: Mean age was 83±13 years (75 men). At discharge, 52.2% of
patients were under OAC. Mean CHADS, CHADSVASc and HASBLED
score were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1; all patients had a CHA
DS VASc score ≥2 and 86% a CHADS ≥2. The HASBLED score was asso-
ciated with non-prescription of anticoagulation (p=0.001), while none of the
thrombo-embolic scores was significantly associated with prescription. Spe-
cific studied parameters are in table.
Conclusion: In our study of everyday practice, there is an underuse of anti-
coagulation in the elderly compared to guidelines, mainly because the percep-
tion of the hemorrhagic risk prevails over the thrombo-embolic risk. Specific
geriatric parameters could help to choose the appropriate therapy.
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Introduction: Age is a major thrombo-embolic risk factor in atrial fibril-
lation (AF), but also a risk factor for bleeding under oral anticoagulation
therapy (OAC). However, it appears that older patients are inadequately
treated with OAC.
The objective of our study was to evaluate the use of OAC in elderly
patients hospitalised in a cardiology department according to current guide-
lines.
Method: Over a 4-month period, 142 patients over 75 years old with his-
tory of AF were included. Clinical and biological data were recorded, and risk
scores for bleeding (HASBLED) and thrombo-embolic events (CHADS2 and
CHA2DS2VASc) were independently assessed after discharge. The differences
between bleeding and thrombo-embolic risk were calculated for each patient.
Patients with OAC at discharge and patients without OAC were compared.
Results: Mean age was 83±13 years (75 men). Mean CHADS, CHADS-
VASc and HASBLED scores were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1.
According to CHADSVASc score and guidelines all of the patients were
eligible for OAC. However 47.8% of patients were not under OAC. Those
patients were older (84.6±0.6 vs. 81.8±0.5; p=0.001), predominantly female
(66 vs. 35%; p=0.001) with a higher serum creatinine (127.3±7.3 vs. 106±6.3;
p=0.03) and HASBLED score (2.7 vs. 2.16; p=0.001). OAC use was not asso-
ciated with CHADS and CHADSVASc scores values.
Conclusion: Our study in daily pratice confirms that OAC in older patients
with AF are underused and that the bleeding risk may be over-rated and/or
thrombo-embolic risk under-estimated. However, specific risk factors in older
patients may not be included in currently used scores.
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Introduction: Characteristics of patients with atrial fibrillation (AF) are
well known, however the patients included in published studies are usually
younger than patients encountered in daily practice in hospital.
Anticoagulation
=74
o anticoagulation
=68
p
Age (years) 81.8±0.5 84.6±0.6 0.001
Creatinine (µmol/l) 106±7.3 127.3±6.3 0.03
Dependency (%) 27 54 0.001
Dementia (%) 4,1 14,7 0.04
High risk of falling (%) 0 20 0,001
MMS score 21.4±1.2 20.1±1.1 NS
ADL score 5.1±0.3 3.8±0.4 0.001
IADL score 2±0.2 2.4±0.4 NS
OAC o OAC
T (CHADS) >B 49.2% 39%*
T (CHADS) < B 2.3%µ 9.2%
T (CHADSVASC) >B  47%  40%*
T (CHADSVASC) < B 3.8%µ 8.4%
T: Thrombo-embolic risk; B: bleeding risk (HASBLED) according to scores
*: undertreated patients according to scores
µ: over-treated patients according to scores
